Advances in the Treatment of Generalized Myasthenia Gravis: Which of Your Patients May Benefit from Targeted Immunotherapies?

FACULTY

James F. Howard Jr., MD
Professor of Neurology, Medicine & Allied Health
Department of Neurology–Neuromuscular Division
The University of North Carolina at Chapel Hill
Professor of Clinical Sciences (Neurology)
Department of Clinical Sciences (Neurology)
North Carolina State College of Veterinary Medicine
Raleigh, NC

Jeff Guptill, MD, MA, MHS
Professor of Neurology
Director, Duke Early Phase Clinical Research Unit
Duke Clinical Research Institute (DCRI)
Department of Neurology–Neuromuscular Medicine
Duke University School of Medicine
Durham, NC

PROGRAM OVERVIEW

This enduring activity focuses on the treatment and management of patients with generalized myasthenia gravis (gMG).

TARGET AUDIENCE

This activity is intended for neuromuscular, neuroimmunology, neuro-ophthalmology, general neurology, and advanced care practitioners such as nurse practitioners, doctors of pharmacy/registered pharmacists, and physician assistants involved in the management of patients with generalized MG.

LEARNING OBJECTIVES

On completing this program, attendees should be able to:

  • Select appropriate treatments for patients with generalized MG based on their specific clinical characteristics
  • Assess results from clinical trials evaluating emerging targeted therapies for the treatment of patients with generalized MG
  • Predict the potential benefits of emerging targeted therapies for the treatment of generalized MG

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment and/or management of patients with generalized MG.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Guptill provided the following disclosures:

Relationship Manufacturer
Consultant Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., argenx, Becton, Dickinson and Company (BD), Cabeletta Bio, Janssen Pharmaceuticals, Immunovant, Inc., Momenta Pharmaceuticals, Inc., Piedmont Pharmaceuticals, Ra Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Toleranzia, and UCB Pharma
Grant/research support: Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, and NIH (NIAID, NINDS, NIHM)
Grant for fellowship training UCB Pharma
Site investigator Alexion, argenx, Janssen, Takeda Pharmaceutical Company, and UCB Pharma

Dr. Howard provided the following disclosures:

Relationship Manufacturer
Advisory board member Alexion Pharmaceuticals, Inc., argenx BVBA, Cartesian Therapeutics, Immunovant, Inc., Regeneron Pharmaceuticals, Inc., Sanofi USA, Toleraniza AB, Viela Bio, Inc. (now Horizon Therapeutics)
Site investigator Alexion Pharmaceuticals, argenx BVBA, Millennium Pharmaceuticals, Inc., PCORI, Ra Pharmaceuticals (UCB), Centers for Disease Control and Prevention

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Russie Allen, Accreditation and Outcomes Manager, has nothing to disclose.
  • Andrew D. Bowser, ELS, CHCP, Medical Director for Med Learning Group, has nothing to disclose.
  • Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
  • Naomi De Brito, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASE DATE: February 25, 2022

EXPIRATION DATE: February 25, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.